Serum antibodies to JCV, BKV, and SV40 and their relation to the risk of a subsequent primary malignant brain tumor, Washington County, MD, 1975–2000
| Polyomavirus antibodies . | Cases . | . | Controls . | . | Matched OR . | 95% CI . | ||
|---|---|---|---|---|---|---|---|---|
| . | n . | (%) . | n . | (%) . | . | . | ||
| JCVa | ||||||||
| <640 | 8 | (18.2) | 22 | (25.0) | 1.00 | |||
| 640 or 2560 | 22 | (50.0) | 41 | (46.6) | 1.44 | (0.57–3.64) | ||
| ≥10240 | 14 | (31.8) | 25 | (28.4) | 1.49 | (0.55–4.07) | ||
| ≥640 | 36 | (81.8) | 66 | (75.0) | 1.46 | (0.61–3.50) | ||
| BKVa | ||||||||
| <640 | 8 | (18.2) | 12 | (13.6) | 1.00 | |||
| 640 or 2560 | 17 | (38.6) | 39 | (44.3) | 0.61 | (0.19–1.94) | ||
| ≥10240 | 19 | (43.2) | 37 | (42.0) | 0.72 | (0.23–2.27) | ||
| ≥640 | 36 | (81.8) | 76 | (86.4) | 0.66 | (0.22–1.95) | ||
| SV40b | ||||||||
| Negative | 39 | (88.6) | 78 | (88.6) | 1.00 | |||
| Weak positivec | 1 | (2.3) | 4d | (4.5) | 0.45 | (0.04–4.82) | ||
| Positivec | 4 | (9.1) | 6 | (6.8) | 1.33 | (0.35–5.11) | ||
| Positivee | 5 | (11.4) | 10d | (11.4) | 1.00 | (0.30–3.32) | ||
| Polyomavirus antibodies . | Cases . | . | Controls . | . | Matched OR . | 95% CI . | ||
|---|---|---|---|---|---|---|---|---|
| . | n . | (%) . | n . | (%) . | . | . | ||
| JCVa | ||||||||
| <640 | 8 | (18.2) | 22 | (25.0) | 1.00 | |||
| 640 or 2560 | 22 | (50.0) | 41 | (46.6) | 1.44 | (0.57–3.64) | ||
| ≥10240 | 14 | (31.8) | 25 | (28.4) | 1.49 | (0.55–4.07) | ||
| ≥640 | 36 | (81.8) | 66 | (75.0) | 1.46 | (0.61–3.50) | ||
| BKVa | ||||||||
| <640 | 8 | (18.2) | 12 | (13.6) | 1.00 | |||
| 640 or 2560 | 17 | (38.6) | 39 | (44.3) | 0.61 | (0.19–1.94) | ||
| ≥10240 | 19 | (43.2) | 37 | (42.0) | 0.72 | (0.23–2.27) | ||
| ≥640 | 36 | (81.8) | 76 | (86.4) | 0.66 | (0.22–1.95) | ||
| SV40b | ||||||||
| Negative | 39 | (88.6) | 78 | (88.6) | 1.00 | |||
| Weak positivec | 1 | (2.3) | 4d | (4.5) | 0.45 | (0.04–4.82) | ||
| Positivec | 4 | (9.1) | 6 | (6.8) | 1.33 | (0.35–5.11) | ||
| Positivee | 5 | (11.4) | 10d | (11.4) | 1.00 | (0.30–3.32) | ||
Antibody titers measured by ELISA.
Antibodies measured by plaque neutralization assay.
Weak positive is defined as positive at 1:10 serum dilution and negative at 1:40 dilution; positive is defined as positive at both dilutions.
Includes one specimen that was positive at the 1:10 dilution but could not be interpreted at the 1:40 dilution.
This positive category includes both weak positives and positives.